Skip to main content
Adam Luginbuhl, MD, Otolaryngology (ENT), Philadelphia, PA, Thomas Jefferson University Hospital

AdamLuginbuhlMD

Otolaryngology (ENT) Philadelphia, PA

Head & Neck Microvascular Surgery, Head & Neck Oncologic Surgery

Assistant Professor, Otolaryngology, Thomas Jefferson University

Dr. Luginbuhl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Luginbuhl's full profile

Already have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Head & Neck Surgical Oncology/Microvascular Reconstruction, 2012 - 2013
  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Otolaryngology - Head and Neck Surgery, 2007 - 2012
  • Uconn School Of Medicine
    Uconn School Of MedicineClass of 2007
  • University of Pennsylvania
    University of PennsylvaniaB.S., 2002

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2013 - 2025
  • DE State Medical License
    DE State Medical License 2021 - 2025
  • PA State Medical License
    PA State Medical License 2007 - 2024
  • TN State Medical License
    TN State Medical License 2012 - 2013
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
  • 3rd Place for Basic Science Research Eastern Triologic Resident Competition, 2011
  • AOA Teaching Award Thomas Jefferson University, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Positive Initial Margins with Survival Among Patients with Squamous Cell Carcinoma Treated with Total Laryngectomy  
    Corey Savard, David Cognetti, Michael C Topf, William Keane, Joseph Curry, Patrick Tassone, Adam Luginbuhl, JAMA
  • Prospective Randomized Controlled Trial Using Best-Selling Smoking Cessation Book  
    Foshbee J, Oh Anita, Curry J, Keane, W, Cognetti, D, ENT Journal, 1/1/2015
  • Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments  
    Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J, Tuluc M, Campling B, Axelrod R, Seminars in Oncology Journal, 1/1/2014
  • Join now to see all

Abstracts/Posters

  • Cervical Spine Osteomyelitis after Esophageal Dilation in Patients with a History of Laryngectomy or Pharyngectomy and Pharyngeal Irradiation
    Souza J, Goldman R, Curry J, Heller J, Cognetti D, American Head Neck Society 5thAnnual Meeting, New York, NY, 1/1/2014
  • Management of the External Auditory Canal in Free Flap Reconstruction of Total Auriculectomy Defects
    Artz G, Cognetti D, Curry J, Heffelfinger R, Krein H, American Head Neck Society 5thAnnual Meeting, New York, NY, 1/1/2014
  • Transoral Robotic Surgery for Parapharyngeal Space Tumors
    Nguyen A, Cognetti D, Triologic Society Meeting, Phoenix, AZ, 1/1/2011
  • Join now to see all

Lectures

  • Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Novel therapeutic approach using triterpenoid RTA to prevent radiation-associated tissue injury and fibrosis in rodent model 
    Boston, MA - 1/1/2015
  • Oropharyngeal Cancer in the 20th Century 
    Princeton Medical Center, Princeton, NJ - 1/1/2014
  • Join now to see all

Press Mentions

  • Expanding on Liquid Biopsies with Exosomes
    Expanding on Liquid Biopsies with ExosomesApril 1st, 2015
  • Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)
    Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)October 21st, 2023

Hospital Affiliations